Zhejiang Medicine Co Ltd
SSE:600216
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zhejiang Medicine Co Ltd
SSE:600216
|
CN |
|
A
|
Apollomics Inc
NASDAQ:APLM
|
US |
|
Total Bangun Persada Tbk PT
F:T9Q
|
ID |
|
Self Storage Management S de RL de CV
BMV:STORAGE18
|
MX |
|
Wee-Cig International Corp
OTC:WCIG
|
US |
|
Entrust Inc
TSE:7191
|
JP |
|
Saudi Ceramic Company SJSC
SAU:2040
|
SA |
|
Shihlin Electric & Engineering Corp
TWSE:1503
|
TW |
|
Bank of Hawaii Corp
NYSE:BOH
|
US |
Wall Street
Price Targets
Price Targets Summary
Zhejiang Medicine Co Ltd
According to Wall Street analysts, the average 1-year price target for
Zhejiang Medicine Co Ltd
is 18.11 CNY
with a low forecast of 17.17 CNY and a high forecast of 19.43 CNY.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Zhejiang Medicine Co Ltd's stock price target?
Price Target
18.11
CNY
According to Wall Street analysts, the average 1-year price target for
Zhejiang Medicine Co Ltd
is 18.11 CNY
with a low forecast of 17.17 CNY and a high forecast of 19.43 CNY.
What is Zhejiang Medicine Co Ltd's Revenue forecast?
Projected CAGR
0%
For the last 13 years the
compound annual growth rate for
Zhejiang Medicine Co Ltd's revenue is
5%.
The projected
CAGR
for the next 3 years is
0%.
What is Zhejiang Medicine Co Ltd's Operating Income forecast?
Projected CAGR
1%
For the last 13 years the
compound annual growth rate for
Zhejiang Medicine Co Ltd's operating income is
1%.
The projected
CAGR
for the next 3 years is
1%.
What is Zhejiang Medicine Co Ltd's Net Income forecast?
Projected CAGR
4%
For the last 13 years the
compound annual growth rate for
Zhejiang Medicine Co Ltd's net income is
1%.
The projected
CAGR
for the next 3 years is
4%.
